The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to .sup.99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives stabilized .sup.99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.

A process for producing a metal-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a metal source to provide a metal-Mo composition. The metal-Mo composition can be pH adjusted with a base to precipitate a plurality of metal-Mo particulates.

A theragnostic method is here described for treating a subject affected by a neoplasia by administering in both the diagnostic and therapeutic steps the same radioisotope, which is a .sup.64Cu.sup.++ salt. Such method comprises a diagnostic step to select a subject, in which there is .sup.64Cu.sup.++ cellular uptake. In case there is no uptake, the treatment is not advisable. In case there is copper uptake from cancer lesions, this has a predictive value of response to treatment. If the subject is selected for the treatment, the method further comprises a step of treating cancer in said subject by administering a therapeutically effective amount of the same .sup.64Cu.sup.++ salt.

The disclosure pertains to a strontium-90 sealed radiological or radioactive source, such as may be used with treatment of the eye or other medical or industrial processes. The sealed radiological source includes a radiological insert within an encapsulation. The encapsulation may include increased shielding in the center thereof.

A process for producing a metal-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a metal source to provide a metal-Mo composition. The metal-Mo composition can be pH adjusted with a base to precipitate a plurality of metal-Mo particulates.

The present invention relates to the use of radiopharmaceuticals having a radioactive half-life of less than 21 minutes, such as oxygen-15 labeled water (H.sub.2.sup.15O) in blood flow imaging using PET (Positron emission tomography) scanning technology. The invention also relates to the use of a system for preparing and injecting boluses of such radiopharmaceuticals.

The present invention relates to an aryl ethene derivative, for inhibiting an estrogen-related receptor gamma (ERRγ) activity, a prodrug of same, a solvate of same, a stereoisomer of same or pharmaceutically acceptable salts of same, and a pharmaceutical composition containing same as an active ingredient.

A process for producing a metal-molybdate material is provided. The process includes a step of reacting a metal molybdenum (Mo) material in a liquid medium with a first acid to provide a Mo composition and combining the Mo composition with a metal source to provide a metal-Mo composition. The metal-Mo composition can be pH adjusted with a base to precipitate a plurality of metal-Mo particulates.

The present disclosure relates to a method for labeling a radioisotope, a radiolabeling compound, a kit including the same, and a method for labeling a radioisotope, including: providing a diaminophenyl compound represented by Chemical Formula I below and including a biomolecule, a fluorescent dye or a nanoparticle compound bound thereto; and reacting the diaminophenyl compound and a radioisotope-labeled aldehyde compound represented by Chemical Formula II below at room temperature; and a related technology: ##STR00001## in Chemical Formula I, A is CH.sub.2 or O; a is 0 or an integer of 1 to 10; X is CH.sub.2 or —CONH—; Y is CH.sub.2 or ##STR00002##  and Z is the biomolecule, the fluorescent dye or the nanoparticle compound, ##STR00003## in Chemical Formula II, b is 0 or an integer of 1 to 10; and L is CH.sub.2 or —CONH—; and Q is ##STR00004## M, M′ and M″ in Q are radioisotopes.

Embodiments of the invention provide methods of synthesizing .sup.18F-tetrafluoroborate (.sup.18F-TFB) via direct radiofluorination on boron trifluoride (BF.sub.3) to enhance both labeling yield and specific activity. Uses of .sup.18F-TFB are also contemplated.